Hetero Healthcare Ltd Introduces Hetran, Pioneering a New Generation of Acid Blockers

Unlike available therapies, the onset of action of Vonoprazan starts right from the first dose. Vonoprazan competitively and reversibly blocks the potassium binding site of H+/K+ATPase, allowing a longer duration of action. Additionally, it can be administered independently of food and has minimal drug-drug interactions.

Mr Sandeep Shastri, Executive Director, Hetero Healthcare Ltd said, “With the introduction of Vonoprazan under the brand name Hetran for the first time in India, we are dedicated to providing relief to patients suffering from gastric acid disorders. Numerous studies have shown Vonoprazan's superior efficacy in treating esophagitis and other acid-related disorders, providing rapid and sustained relief compared to conventional therapies”.

He further added, “Proton pump inhibitors fail to adequately control symptoms in up to 40% of patients with reflux diseases. We take pride in bringing this new-age acid blocker, Vonoprazan for the first time in India for the management of acid-related disorders. Hetero Healthcare Ltd is the basic manufacturer of Vonoprazan in the country”.

Hetero Healthcare Ltd, headquartered in Hyderabad, is a pharmaceutical manufacturing company that operates globally in the active pharmaceutical ingredient (API) and generic formulations businesses.

Disclaimer: This post has been published under MD Brand Connect Initiative and is sponsored by Hetero Healthcare Ltd.